RNAimmune is a biotechnology startup in the field of messenger RNA (mRNA) technology with more than 20 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of RNAimmune's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines.
We develop prophylactic vaccines to help immune systems build responsive mechanisms against serious infectious diseases.
We develop individualized neoantigen based therapeutic vaccines to treat cancer. We also provide early detection and companion diagnosis
We develop mRNA-based therapeutics to treat difficult rare diseases.
RNAimmune’s development pipelines currently focus on mRNA-based vaccines that protect against cancer and respiratory viruses, alongside the development of mRNA cancer immunotherapies.
We’ve developed a synthetic biology based, artificial intelligence aided platform that help us design better mRNAs to invoke the optimal response from our immune system. Current projects that are enabled by our platform include multi-target prophylactic vaccines and cancer vaccines expressing tumor-targeted epitopes.
We have developed several proprietary and novel mRNA delivery methods including lipid nanoparticle (LNP) formulations and Polypeptide Lipid Nanoparticle (PLNP) based carriers. We are able to deliver a wider variety of mRNAs with enhanced intracellular expression and targeted delivery.
We are leveraging advancements in computational protein engineering to optimize vaccines at the protein level for a stronger and more protective immune response.
Our novel self-amplifying mRNAs provide stronger and longer potency for each treatment.
RNAimmune successfully submitted IND application for RSV mRNA vaccine to China Center for Drug Evaluation (CDE) (read more)
RNAimmune licensed out the RV-1770 human RSV Vaccine to Hualan Biological Vaccine Inc. (read more)
FDA Approves RNAimmune’s New mRNA RSV Vaccine for Phase I Trials for Respiratory Disease Prevention (read more)
RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770 (read more)
Innoforce’s Partner RNAimmune Granted IND Clearance for RSV mRNA Vaccine from FDA (read more)
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit (read more)
Telesis Bio and RNAimmune’s David Brown to Present at SynBioBeta 2023 (read more)
Drug Product Filled with Berkshire Sterile’s Low Loss Fill Process Receives FDA Green Light (read more)
RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase I Trial of RV-1730 COVID-19 Booster Vaccine (read more)
RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting (read more)
RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines (read more)
Sirnaomics’ Spin-Off RNAimmune Secures $10 Million Seed Financing to Advance its mRNA-Based Vaccine and Therapeutic Development (read more)
Codex DNA and RNAimmune Announce Collaboration to Optimize Development of Future mRNA Synthesis and Delivery Kits (read more)
RNAimmune accelerates R&D into mRNA vaccine, drug discovery (read more)
Dr. Dong Shen is an innovative biotechnology executive and a leading expert in mRNA technology and cancer therapeutics. As the Founder and CEO of RNAimmune, Inc., a clinical-stage biotechnology company, he has driven the development of mRNA-based vaccines and therapeutics targeting infectious diseases, cancer, and rare genetic disorders. Under his leadership, RNAimmune has achieved significant milestones, including FDA clearance for clinical trials and the development of next-generation mRNA vaccine candidates. Dr. Shen has played a pivotal role in incorporating artificial intelligence (AI) and machine learning (ML) into mRNA vaccine and therapeutic development, advancing precision and efficacy in vaccine design.
Address
15601 Crabbs Branch Way, Suite W106, Derwood, MD 20855
Contact
hello@rnaimmune.com
Connect with us on LinkedIn
